This article is more than 5 years old. Information may no longer be current.
Top oncology stories: Stem cell transplant extends survival for multiple myeloma; Keytruda receives FDA priority review for new indication
Click Here to Manage Email Alerts
This week, the top story in hematology/oncology was a report that found that autologous hematopoietic stem cell transplant extends survival for individuals with newly diagnosed multiple myeloma but is used infrequently.
Other top stories included the formation of OneOncology, a new company devoted to improving cancer care; the FDA granting priority review to Keytruda for the expansion of indications to include non-small cell lung cancer with PD-L1 expression; phase 2 trial findings that revealed that obinutuzumab-venetoclax appeared safe and effective for treatment of patients with chronic lymphocytic leukemia; and study results that indicated that Capizzi-style methotrexate improves survival in pediatric T-cell acute lymphoblastic leukemia.
Autologous hematopoietic stem cell transplant underused despite survival benefits for newly diagnosed multiple myeloma
Autologous hematopoietic stem cell transplant extends survival for individuals with newly diagnosed multiple myeloma but is used infrequently for this patient population, according to findings published in Journal of the National Cancer Institute. Read more.
Three community oncology practices join forces to ‘transform’ cancer care delivery
Three community oncology practices have formed OneOncology, a company with a mission to improve cancer care through patient-centric and technology-driven innovations. Read more.
FDA grants priority review to Keytruda for PD-L1-positive non-small cell lung cancer
The FDA granted priority review designation to a supplemental biologics license application for pembrolizumab for the treatment of non-small cell lung cancer with PD-L1 expression of at least 1%, according to the manufacturer. Read more.
Obinutuzumab-venetoclax shows activity for chronic lymphocytic leukemia
Bendamustine followed by obinutuzumab and venetoclax appeared safe and effective for treatment of patients with chronic lymphocytic leukemia, according to results from the open-label, phase 2 CLL2-BAG trial. Read more.
Capizzi-style methotrexate improves survival in pediatric T-cell acute lymphoblastic leukemia
Capizzi-style methotrexate without leucovorin rescue induced superior outcomes compared with high-dose methotrexate with leucovorin rescue among children with T-cell acute lymphoblastic leukemia, according to study results from the Children’s Oncology Group AALL0434 trial. Read more.